Manufacturer record

Skylink Pharma: regulatory record

Last checked 20 September 2026. Source: CDSCO monthly NSQ alerts and state drug-testing laboratories

1 batch manufactured by Skylink Pharma (Gujarat) were declared Not of Standard Quality between June 2026 and June 2026. Records are batch-specific findings by government laboratories as published in CDSCO's monthly alerts; where a company has stated that a flagged batch was counterfeit, that statement is noted when reported.

Records by type

1 record linked to Skylink Pharma in the datasets we hold. A zero means nothing is on record in those datasets, not that nothing ever happened. What the labels mean.

0Banned or prohibited
0Recalled or suspended
1Failed a lab test
0Regulatory notice
Primary government sourceTier 1: government primary source

CDSCO drug alerts: Not of Standard Quality and spurious drugs

CDSCO · CDSCO monthly NSQ alerts, Jun 2026 to Jun 2026

View original document

Scope. A company appearing here is not a finding that its products are unsafe. Regulatory actions can apply to one batch, one formulation, one period or one state. Always check the linked government document for the current position, and tell us if something is out of date. How we label records.

1
NSQ batches since 2026
1
Products affected
Microbial limits
Most common failure
Jun 2026
Latest alert

Flagged batches per year

2026 · 1

All flagged batches

Product Batch Reason declared NSQ Tested by Alert
Paracetamol Paediatric Oral Suspension IP 250mg, 60ml SL25156Mfg 2026-03 · Exp 2028-02 The sample does not conform to as per I.P. 2022 with respect to the test of Microbial contamination (Total aerobic viable count).Microbial limits CDTL, MumbaiCDSCO lab Jun 2026

Right of reply. Manufacturers may submit a response or a laboratory re-test result; it is published unedited alongside this record. Submit a response.